Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 6/20 | 0.73 |
| ▸ | MEN1 | O00255 | 5/20 | 0.73 |
| ▸ | MAPT | P10636 | 5/20 | 0.73 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.73 |
| ▸ | HTT | P42858 | 3/20 | 0.73 |
| ▸ | NPC1 | O15118 | 3/20 | 0.73 |
| ▸ | RAB9A | P51151 | 3/20 | 0.73 |
| ▸ | LMNA | P02545 | 2/20 | 0.73 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.73 |
| ▸ | AURKA | O14965 | 1/20 | 0.73 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.73 |
| ▸ | JAK2 | O60674 | 1/20 | 0.73 |
| ▸ | GMNN | O75496 | 1/20 | 0.73 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.73 |
| ▸ | EGFR | P00533 | 1/20 | 0.73 |
| ▸ | TP53 | P04637 | 1/20 | 0.73 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.73 |
| ▸ | LYN | P07948 | 1/20 | 0.73 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.73 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.73 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28461642 | 0.89 | KMT2A (0.73) | KMT2AMEN1MAPTSMN1; SMN2HTT | |
| SCHEMBL22032660 | 0.88 | KMT2A (0.88) | KMT2AMEN1MAPTSMN1; SMN2HTT | |
| SCHEMBL29617487 | 0.88 | KMT2A (0.88) | KMT2AMEN1MAPTSMN1; SMN2HTT | |
| SCHEMBL11764083 | 0.87 | HTT (0.59) | KMT2AMEN1MAPTSMN1; SMN2HTT | |
| SCHEMBL11764394 | 0.85 | HTT (0.72) | KMT2AMEN1MAPTSMN1; SMN2HTT | |
| SCHEMBL29617478 | 0.85 | KMT2A (0.78) | KMT2AMEN1MAPTSMN1; SMN2HTT | |
| SCHEMBL16160831 | 0.85 | KMT2A (0.78) | KMT2AMEN1MAPTSMN1; SMN2HTT | |
| Niclosamide SCHEMBL16686086 | 0.85 | KMT2A (0.95) | KMT2AMEN1MAPTSMN1; SMN2HTT | |
| SCHEMBL25346525 | 0.84 | KMT2A (0.81) | KMT2AMEN1MAPTSMN1; SMN2HTT | |
| Niclosamide SCHEMBL6662409 | 0.84 | KMT2A (1.00) | KMT2AMEN1MAPTSMN1; SMN2HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180370905-A1 | Compounds Useful for the Treatment of Metabolic Disorders and Synthesis of the Same | NORTH CAROLINA CENTRAL UNIV (US) | 2018-12-27 | — | — | US | disclosed |
| US-10005720-B2 | Compounds useful for the treatment of metabolic disorders and synthesis of the same | NORTH CAROLINA CENTRAL UNIVERSITY (US) | 2018-06-26 | — | — | US | disclosed |
| US-10005720-B2 | Compounds useful for the treatment of metabolic disorders and synthesis of the same | NORTH CAROLINA CENTRAL UNIVERSITY (US) | 2018-06-26 | — | — | US | disclosed |
| US-20160046560-A1 | COMPOUNDS USEFUL FOR THE TREATMENT OF METABOLIC DISORDERS AND SYNTHESIS OF THE SAME | NORTH CAROLINA CENTRAL UNIVERSITY | 2016-02-18 | — | — | US | disclosed |
| US-20160046560-A1 | COMPOUNDS USEFUL FOR THE TREATMENT OF METABOLIC DISORDERS AND SYNTHESIS OF THE SAME | NORTH CAROLINA CENTRAL UNIVERSITY | 2016-02-18 | — | — | US | disclosed |
| WO-2014165816-A1 | COMPOUNDS USEFUL FOR THE TREATMENT OF METABOLIC DISORDERS AND SYNTHESIS OF THE SAME | NORTH CAROLINA CENTRAL UNIVERSITY (US) | 2014-10-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10005720-B2 | Compounds useful for the treatment of metabolic disorders and synthesis of the same | GLS2, PC, GLS | KMT2A 1812/4885MEN1 1171/4885MAPT 2394/4885 |
| US-20180370905-A1 | Compounds Useful for the Treatment of Metabolic Disorders and Synthesis of the Same | GLS2, PC, GLS | KMT2A 1812/4885MEN1 1171/4885MAPT 2394/4885 |
| US-20160046560-A1 | COMPOUNDS USEFUL FOR THE TREATMENT OF METABOLIC DISORDERS AND SYNTHESIS OF THE SAME | GLS2, PC, GLS | KMT2A 1812/4885MEN1 1171/4885MAPT 2394/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.